Background: The eighth most frequent gynecologic cancer in the world is ovarian cancer. Due to its advanced state at diagnosis, it is the worst gynecological cancer. The high mortality rate is largely due to the tendency to early spreading in the abdominal cavity, and most ovarian cancers being diagnosed at advanced stages (FIGO stage III & IV). Despite a high response rate to platinum-based chemotherapy, the overall survival (OS) remains poor with a 5-year overall survival of only 30–40%. Objective: The aim of this study is to Compare the Overall Survival, Progression Free Survival (PFS), Treatment Free Interval (TFI), Platinum Sensitive Recurrence (PSR) & Platinum resistant Recurrence (PRR) in patients with BRCA mutation and without BRCA mutation. Methods: The longitudinal cohort study was conducted in the Department of Gynecological Oncology, Bangabandhu Sheikh Mujib Medical University (BSMMU) & NICRH Dhaka. A total 30 women with histopathologically confirmed advanced stage (FIGO stage III & IV) serous epithelial ovarian cancer were included in the study. Participants were divided into two groups: patients with BRCA1 associated epithelial ovarian cancer and those patients with BRCA2 associated epithelial ovarian cancer. The questionnaire was pretested, corrected and finalized. Data were collected by face-to-face interview and analyzed by appropriate computer based programmed software Statistical Package for the Social Sciences (SPSS), version 24. Results: In this study, maximum study subjects 17 (80.9%) were in ≤45 years age group in BRCA1 associated EOC group and 6 (66.6%) were in >45 years age group in unexposed group. Mean age of the study subjects was 42.3±3.5 and 30.23±4.4 years in BRCA1 associated EOC and BRCA2 associated EOC group respectively. Majority of the patients 17 (80.9%) and 18 (85.7%) 6 (66.6%) were literate and 4 (19.1%) and 3 (33.3%) were illiterate in BRCA1 associated EOC and BRCA2 associated EOC group respectively. About 9 (42.9%) respondent of BRCA1 associated EOC group and 6 (66.6%) of BRCA2 associated EOC group had family history of breast / ovarian cancer. Conclusion: For epithelial ovarian cancer patients who received chemotherapy, we confirmed survival benefit for BRCA1 and BRCA2 germline pathogenic variant carriers. This may indicate higher sensitivity to chemotherapy, both in first line treatment and in the recurrent setting. The observed benefit appears to be limited to a relatively short period after epithelial ovarian cancer diagnosis.